IMC Chicago
CRL icon

IMC Chicago’s Charles River Laboratories CRL Stock Holding History

IMC Chicago’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.3M Buy
+24,900
New +$4.62M ﹤0.01% 1906

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

IMC Chicago's CRL Position: Q1 2026 in Review

IMC Chicago opened a new position in Charles River Laboratories (CRL) in Q1 2026: 7,293 shares worth $1.26M. The stake represents ﹤0.01% of the portfolio and ranks #3043 among its holdings.

557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • IMC Chicago held 7,293 shares of Charles River Laboratories worth $1.26M as of Q1 2026.
  • Charles River Laboratories was a new IMC Chicago position in Q1 2026.
  • Charles River Laboratories made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #3043 holding.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.